Skip to main content
Caplight Logo









D2B3

D2B3

Private
New Haven, ConnecticutHealthcare & Life Scienceshttps://d2b3.bio/

Last Round

Pre Seed

Jun 1, 2024

Total Funding Raised

$500,000

Company Overview

D2B3 is a biotechnology company that operates a pre-clinical platform intended to advance drug delivery to the brain and central nervous system.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

blood-brain barrier deliveryBBB deliverydrug delivery platformmonoclonal antibodybrain shuttlecentral nervous systemCNSblood-brain barrier modulationbiologics deliveryCNS therapeuticsglioblastomabrain tumor treatmentpre-clinical biotechbiotech partnershipsneurodegenerative disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

D2B3 Comparables

Compare D2B3 with similar companies based on industry and business-model similarity.

D2B3 comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Qinotto, Inc.
83%
Gate2Brain
82%
Sylamore Bio
76%

D2B3 Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedJun 1, 2024

Key People

Founding team and executive leadership

Manuel Mohr

Co-Founder & CEO

Founding Team

D2B3 Investors

Notable investors and investment history

D2B3 investors
InvestorRounds
Connecticut InnovationsPre Seed
Alexandria LaunchLabsPre Seed
Yale VenturesPre Seed
Mission BioCapitalPre Seed
SOSVPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2024

    $500K round led by Mission BioCapital.

D2B3 Filings

Explore SEC and related filing metadata, where available.

D2B3 filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about D2B3's valuation, stock price, and market status.

Is D2B3 a public or private company?

D2B3 is a private company.

What is the current stock price of D2B3?

D2B3 is a private company with no public stock price. No recent secondary market data is available.

How much is D2B3 worth (valuation)?

Valuation information for D2B3 is not publicly available.

Can I buy D2B3 stock?

D2B3 shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was D2B3's last funding round?

D2B3's most recent funding round was Pre Seed on June 1, 2024.

Who are the main investors in D2B3?

Key investors in D2B3 include Mission BioCapital.

Will D2B3 IPO soon?

No public IPO plans have been announced for D2B3.

How can I track D2B3 secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor D2B3's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew Haven, Connecticut
Employee Range4
Year Founded2024
Last FundingJun 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?